ALL requires immediate treatment, often a combination of chemotherapy, targeted therapy, immunotherapy and bone marrow transplants—but clinicians today have no way of knowing how specific drug combinations and dosages will impact the patient, or whether the treatment will be successful.
Currently, treatment strategies incorporate some degree of personalization based on leukemia subtype and risk classification. Despite this, most patients ultimately receive similar treatment regimens.